"What has been missing is the patient's perspective," says one industry consultant. The future of clinical pathways is patient-centric: an approach that balances the long-standing focus on ...
The US Food and Drug Administration (FDA) has submitted its budget proposal to Congress, outlining its spending priorities for fiscal year 2027. The budget request totals $7.2 billion, including $3.3 ...
Expanding the Multidisciplinary Team in Prediagnostic Care of Lung Cancer: How Else Can We Improve Time to Targeted Treatment in Metastatic Non–Small-Cell Lung Cancer? In the article that accompanies ...
EHS has achieved a milestone in healthcare digital transformation through the implementation of multiple clinical pathways that are embedded within the Oracle Health Foundation Electronic Health ...
Millions of people worldwide suffer from AD, a progressive and complex neurological illness that is the primary cause of dementia 1. Like other forms of dementia, the risk increases with age, but it ...
As healthcare becomes more entrenched in the digital revolution, the need for an approved set of protocols for care delivery — clinical pathways — is becoming increasingly critical. Clinical pathways, ...
Childhood trauma (CT) has been linked to various domains of outcomes in individuals with new-onset psychosis, but the intricate relationships between different types of trauma, clinical symptoms, and ...
Omar Nadeem, MD, shares perspective on the significance of collaborative care in the MM treatment landscape. Ryan Haumschild, PharmD, MS, MBA: Dr Nadeem, as someone who does internal pathways and ...
Glioblastoma Clinical Trial Landscape Expands: Over 200 Companies Advancing Next-Generation Therapies | DelveInsight The glioblastoma clinical trial analysis report delivers important insights into ...
Edward "Ted" Arrowsmith, MD, MPH, medical director for pathways at OneOncology and managing partner at Tennessee Oncology, talks about challenges and changes in clinical pathways and the importance of ...
Clinical trial sponsors expanding studies across Europe often face complex regulatory pathways for sample testing, particularly when assays must support EU and UK patient cohorts within compliant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results